BioMed Central
Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases
Research article Open Access
Acute viral hepatitis morbidity and mortality associated with 
hepatitis E virus infection: Uzbekistan surveillance data
Makhmudkhan B Sharapov1, Michael O Favorov2,3,4, Tatiana L Yashina5, 
Matthew S Brown3, Gennady G Onischenko6, Harold S Margolis2,7 and 
Terence L Chorba*8
Address: 1Tashkent Pediatric Medical Institute and Central Asia Epidemiology Network, Ministry of Health, Tashkent, Republic of Uzbekistan, 2Division of Viral Hepatitis (World Health Organization Collaborating Center for Research and Reference in Viral Hepatitis), National Center for 
HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 3Coordinating Office for 
Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 4Division of Translational Research, International Vaccine 
Institute, Seoul, Korea, 5Specialty Laboratories, Santa Monica, California, USA, 6Federal Service for Surveillance on Consumer Rights and 
Wellbeing, Ministry of Health and Social Development of the Russian Federation, Moscow, Russia, 7Pediatric Dengue Vaccine Initiative Program, 
International Vaccine Institute, Seoul, Korea and 8Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Email: Makhmudkhan B Sharapov - mbsharapov@yandex.ru; Michael O Favorov - mfavorov@ivi.int; 
Tatiana L Yashina - tyashina@specialtylabs.com; Matthew S Brown - zjc5@cdc.gov; Gennady G Onischenko - depart@gsen.ru; 
Harold S Margolis - hsmargolis@pdvi.org; Terence L Chorba* - tlc2@cdc.gov
* Corresponding author 
Abstract
Background: In Uzbekistan, routine serologic testing has not been available to differentiate
etiologies of acute viral hepatitis (AVH). To determine the age groups most affected by hepatitis E
virus (HEV) during documented AVH epidemics, trends in AVH-associated mortality rate (MR) per
100,000 over a 15-year period and reported incidence of AVH over a 35-year period were
examined.
Methods: Reported AVH incidence data from 1971 to 2005 and AVH-associated mortality data
from 1981 to 1995 were examined. Serologic markers for infection with hepatitis viruses A, B, D,
and E were determined from a sample of hospitalized patients with AVH from an epidemic period
(1987) and from a sample of pregnant women with AVH from a non-epidemic period (1992).
Results: Two multi-year AVH outbreaks were identified: one during 1975â€“1976, and one during
1985â€“1987. During 1985â€“1987, AVH-associated MRs were 12.3â€“17.8 per 100,000 for the general
population. Highest AVH-associated MRs occurred among children in the first 3 years of life (40â€“
190 per 100,000) and among women aged 20â€“29 (15â€“21 per 100,000). During 1988â€“1995 when
reported AVH morbidity was much lower in the general population, AVH-associated MRs were
markedly lower among these same age groups. In 1988, AVH-associated MRs were higher in rural
(21 per 100,000) than in urban (8 per 100,000) populations (RR 2.6; 95% CI 1.16â€“5.93; p < 0.05).
Serologic evidence of acute HEV infection was found in 280 of 396 (71%) patients with AVH in 1987
and 12 of 99 (12%) pregnant patients with AVH in 1992.
Conclusion: In the absence of the availability of confirmatory testing, inferences regarding
probable hepatitis epidemic etiologies can sometimes be made using surveillance data, comparing
Published: 25 March 2009
BMC Infectious Diseases 2009, 9:35 doi:10.1186/1471-2334-9-35
Received: 19 July 2008
Accepted: 25 March 2009
This article is available from: http://www.biomedcentral.com/1471-2334/9/35
Â© 2009 Sharapov et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 2 of 9
(page number not for citation purposes)
AVH incidence with AVH-associated mortality with an eye to population-based viral hepatitis
control measures. Data presented here implicate HEV as the probable etiology of high mortality
observed in pregnant women and in children less than 3 years of age in Uzbekistan during 1985â€“
1987. High mortality among pregnant women but not among children less than 3 years has been
observed in previous descriptions of epidemic hepatitis E. The high mortality among younger
children observed in an AVH outbreak associated with hepatitis E merits corroboration in future
outbreaks.
Background
In Uzbekistan, there is a high incidence of infection with
hepatitis viruses including the viruses of hepatitis A
(HAV) [1], hepatitis B (HBV) [2], hepatitis C (HCV) [3],
hepatitis D (HDV) [4], and hepatitis E (HEV) [5]. In
1990â€“1995, of all reportable infectious processes, the
number of reported cases of acute viral hepatitis (AVH)
was exceeded only by the cumulative number of cases of
acute respiratory disease [6]. AVH is a reportable disease
in Uzbekistan, where periodic epidemics of fecal-orallyï¿¾transmitted non-A, non-B hepatitis have been described
[7,8]. Elsewhere, in regions in which epidemics of hepatiï¿¾tis E have been observed, increases in mortality among
pregnant women have been reported [9-12].
For reporting purposes in Uzbekistan and other Central
Asian republics of the former Soviet Union, the diagnosis
of hepatitis A has generally been based on signs, sympï¿¾toms and epidemiological data, while the diagnosis of
acute hepatitis B has been based on serologic detection of
hepatitis B surface antigen (HBsAg). However, lack of
serological testing to differentiate hepatitis types has
resulted in official statistics that have generally enumerï¿¾ated cases of AVH with typing of hepatitis A and hepatitis
B only, and reporting of HCV, HDV, and HEV infections
has not been routine.
An indicator of the impact of hepatitis infections is their
associated mortality, most often the result of chronic liver
disease [13]. However, few data exist concerning age- and
gender-specific associations of AVH with mortality. We
analyzed trends in AVH-associated mortality, including
during periods in which hepatitis E epidemics have been
documented [14,15], to determine age- and gender-speï¿¾cific changes in mortality.
Methods
Incidence Reporting
AVH incidence (morbidity) data from 1971 through 2005
were obtained from reports of the Sanitary-Epidemiologic
Service (SES) of the Uzbekistan Ministry of Health
(MOH). These are standardized data from a surveillance
system that was uniformly used by the republics during
the Soviet era [16,17] and that has continued to function
in Uzbekistan since the dissolution of the Soviet Union.
Uzbekistan is organized into 12 provinces, called viloyats,
and one autonomous republic; each of these is subdivided
into administrative units called raions. At each level
(republic, viloyat, raion), the SES has operated an infecï¿¾tious disease surveillance system in which AVH has been
a reportable condition. The system has evolved under a
mandate that requires all suspected or confirmed cases to
be reported by telephone to the raion SES within 12
hours, followed by a written case report [17,18]. These
reports are forwarded to the viloyat SES. Reporting sources
include physicians and feldshers (primary health care proï¿¾viders with less formal training than physicians, found
more commonly in rural areas) who evaluate patients in
hospitals, polyclinics, diagnostic centers, ambulatory clinï¿¾ics, or feldsher stations (rural primary health care clinics).
For each case, health care providers report patient's name,
age, date of birth, sex, address, occupation, day care
attendance, last day of work, polyclinic attended, primary
diagnosis, date of symptom onset, date of physician visit,
date of diagnosis, and date of hospitalization.
Telephone case reports received at the raion SES are
recorded and updated as additional clinical, laboratory
and epidemiologic information is received to help raion
SES staff implement disease control measures. The raion
SES obtains additional information on each case within
24 hours using a standardized case investigation form.
Raion SES staff complete a separate case form which sumï¿¾marizes the information collected during the course of the
epidemiologic and clinical work-up, including clinical
presentation, vaccination status, and laboratory results.
SES epidemiologists may request additional laboratory
testing to confirm the healthcare provider's clinical diagï¿¾nosis. However, lack of reagents to perform diagnostic
testing and lack of strict case definitions have had the
result that most reported cases of AVH in the SES database
reflect clinical diagnoses that have not been laboratory
confirmed.
Raions report AVH case totals to the viloyat SES, and raion
cases are tabulated by age group (total, 0 to 14 years; <1
year (infancy); 1 and 2 years (up to but not including the
third birthday); and 3 to 6 years). Annually, aggregated
data are reported to the viloyat SES. Each month, the vilo-

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 3 of 9
(page number not for citation purposes)
yat SES tabulates confirmed AVH cases by age group, and
reports totals to the republican SES.
Mortality Reporting
AVH-specific mortality data were examined as provided to
the MOH by Goskomstat, the State Committee of Statistics
of the Republic of Uzbekistan, a governmental vital
records agency with its own raion-viloyat-republic reportï¿¾ing hierarchy that is separate from the SES. When a patient
dies, the clinician notifies the hospital or polyclinic statisï¿¾tician, who in turn is responsible for reporting the death
and its putative cause(s) to the statistical administrative
units within Goskomstat that are concerned with mortality.
Case Definition
Although there has been no strict case definition of AVH,
MOH guidelines for clinicians have traditionally defined
AVH as an infectious disease characterized by acute onset
of jaundice, hepatomegaly, and (where available) a threeï¿¾fold or greater elevation of serum aminotransferase levels.
AVH is noted as a cause of death on a death certificate if a
clinician believes the death was a complication of AVH.
Laboratory Methods
During an identified AVH outbreak in 1987, serum samï¿¾ples were collected from a convenience sample of hospiï¿¾talized patients with AVH in Eastern and Southern
Uzbekistan (Fergana and Kashkadarya viloyats) on the
first to seventh day after onset of jaundice; criterion for
hospitalization was onset of jaundice. Similarly, during
1992, serum samples were collected from a convenience
sample of hospitalized pregnant women with AVH in
Tashkent viloyat on the first to seventh day after onset of
jaundice; again, criterion for hospitalization was onset of
jaundice. For both groups, case-patients were defined as
those with acute onset of dyspepsia, jaundice, hepatomeï¿¾galy, and a three-fold or greater increase in serum concenï¿¾trations of alanine aminotrasferase. Serum specimens
were delinked from personal identifiers at the time of colï¿¾lection and were stored at -20Â°C until subsequently
tested. As both of these activities predated implementaï¿¾tion of codified institutional accountability of human
research protections, no standardized consenting process
was employed; however, patient participation was limited
to a solitary phlebotomy for minimal serum samples for
diagnostic purposes.
Serologic testing by enzyme immunoassay (Abbott Laboï¿¾ratories, North Chicago, IL) for markers of infection with
hepatitis viruses was performed at the Viral Hepatitis
Diagnostic Department, Ivanovski Institute of Virology,
Moscow. Testing included assays for markers of acute
HAV infection (IgM anti-HAV); markers of acute HBV
infection, HBsAg and IgM antibody to hepatitis B core
antigen (IgM anti-HBc); and markers of acute HDV infecï¿¾tion (IgM anti-HDV and total anti-HDV). Serum speciï¿¾mens which tested negative for all of the above markers
were retained and subsequently tested in the Hepatitis
Reference Laboratory, Division of Viral Hepatitis,
National Center for Infectious Diseases, Centers for Disï¿¾ease Control and Prevention (CDC), for IgM and IgG antiï¿¾body to HEV (IgM and IgG anti-HEV) using both Western
blot and ELISA [19].
Statistical Methods
Incidence data analyses
To quantify AVH case counts and rates per 100,000 popuï¿¾lation, we analyzed Republican SES reports for the period
1971â€“2005 and specific viloyat reports for 1985â€“1995.
To verify reported rates by viloyat, population counts
from viloyat reports were compared with official
Uzbekistan census data.
Mortality data analyses
To ascertain mortality rates per 100,000 (MRs) from AVH,
AVH-associated mortality data for 1981â€“1995 were
obtained from the Department of Statistics of the Ministry
of Health. AVH-associated MRs for the republic and for
each viloyat for 1985â€“1995 were calculated by age and sex
on the basis of mortality data analyzed from Goskomstat
reports. Where mortality rates per 100,000 population
were calculated for a specific age and sex group, denomiï¿¾nator data were restricted to population estimates for that
specific age and sex group. These analyses did not include
deaths attributed to chronic viral hepatitis and/or cirrhoï¿¾sis.
Statistical analyses
Data were analyzed using Epi Info 6.04 for relative risk
(RR), Student's t-test, correlation analysis (r), Pearson's
conformity test, or Fisher's exact test. Specifically, categorï¿¾ical data were analyzed using Pearson's Ï‡2-test or Fisher's
exact test, as appropriate; Fisher's exact test was used
where categorical data were compared in which any cell
size was <5. Continuous data were analyzed with Stuï¿¾dent's t-test. Statistical significance was determined by calï¿¾culating a p value (with Yates' correction factor where
needed) and exact 95% confidence intervals (CIs), or Tayï¿¾lor series 95% CIs, as appropriate. The significance level
for all statistical analyses was p = 0.05.
Trends in AVH-associated mortality over the 15 years
(1981â€“1995) for which aggregate data were available
were compared with trends in reported AVH incidence
over the same period using the Pearson product-moment
correlation coefficient. For the 11-year period (1985â€“
1995) for which gender- and age-specific AVH-associated
mortality data were available, data were compared by genï¿¾der, age, and rural/urban designation of the decedent
using Pearson's Ï‡2-test, Fisher's exact test, or Student's t-

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 4 of 9
(page number not for citation purposes)
test as appropriate, depending on whether data were cateï¿¾gorical or continuous.
In performing analyses of serology data, IgG anti-HEV
data for various age groups of children were compared
using Pearson's Ï‡2-test.
Results
Reported Incidence
From 1971 through 2005, national reported AVH inciï¿¾dence in Uzbekistan was consistently greater than 200
cases per 100,000 (Fig. 1). Two multi-year epidemics of
AVH were noted: one spanning the years 1975 and 1976
with annual incidences of 1047 and 1072 cases per
100,000, respectively, and another from 1985 through
1987 with annual incidences of 1259, 1187, and 1431
cases per 100,000. Single-year increases in AVH were also
noted in 1973, 1983, 1995 and 1997, with peak inciï¿¾dences ranging from 600 to 1051 per 100,000.
Verification of reported population counts by viloyat
revealed no discrepancies when viloyat reports for hepatiï¿¾tis rates were compared with official Uzbekistan census
data. The geographic distribution of average annual AVH
incidence varied: highest viloyat rates were reported in the
East (Fergana, Namangan, and Andijan) and in the South
(Kashkadarya, Surkhandarya), where incidence in some
viloyats was 1.5- to 1.8-times the national average. In less
densely populated areas, e.g., in the West (Karakaï¿¾lpakstan, Bukhara, and Navoi), incidence tended to be
ulation) Figure 1 Acute viral hepatitis incidence (1971â€“2005) and associated mortality rates (1981â€“1995), by year, Uzbekistan (per 100,000 popï¿¾Acute viral hepatitis incidence (1971â€“2005) and associated mortality rates (1981â€“1995), by year, Uzbekistan 
(per 100,000 population). Left ordinate (y-axis) and line graph: mortality per 100,000 population. Right ordinate (y-axis) and 
bar diagram: reported acute viral hepatitis incidence per population.
0
2
4
6
8
10
12
14
16
18
20
1971
1973
1975
1977
1979
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
Year
Mortality
0
200
400
600
800
1000
1200
1400
1600
Incidence
incidence
mortality

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 5 of 9
(page number not for citation purposes)
lower than the national average except in 1985â€“1987.
Despite higher population density, reported AVH inciï¿¾dence in Tashkent was relatively low and exceeded the
national rate only in 1995 and 1997.
Reported Mortality
AVH-associated mortality varied over 1981 to 1995 and
AVH-associated mortality was closely associated with
reported AVH incidence, r = 0.92; p < 0.001 (Fig. 1). The
highest nationwide AVH-associated mortality occurred in
1987 (17.8 per 100,000) with a corresponding AVH inciï¿¾dence rate of 1,431 per 100,000.
In 1985â€“1995, no significant difference was observed
between males and females: among males, the MR was
11.8 (95%CI: 10.3â€“13.3) per 100,000, and among
females, the MR was 10.8 (95%CI: 9.3â€“12.3) (RR = 1.0;
95%CI: 0.8â€“1.4; p = not significant (n.s.)). When AVHï¿¾associated mortality was examined by age group for all
ages, highest rates were observed in children aged <3 years
(Fig. 2), especially among those aged <2 years; among
both those aged <1 year and those aged â‰¥1 to <2 years, the
peak coincided with the 1987 peak observed in reported
AVH incidence. In Fig 2, gender-specific AVH-associated
mortality for 1985â€“1995 by age group (<1 year, â‰¥1 to <2
years, â‰¥2 to <3 years, 3 to 14 years) is presented in a set of
four bar diagrams. Because reported AVH incidence data
were not available in the same age classifications as AVHï¿¾associated mortality, AVH incidence rate for all age groups
combined is presented as a line diagram above each of the
four bar diagrams to give the reader an appreciation of the
temporal distribution of the AVH-associated age-specific
mortality relative to the overall reported AVH morbidity.
From 1987 to 1995, the AVH-associated MR decreased
among infants (children aged <1 year) from 143.7 to 29.3
per 100,000 (p < 0.01), and among children aged â‰¥1 to <2
years from 166.8 to 30.6 per 100,000 (p < 0.01); markedly
less impressive decreases in rates of AVH-associated morï¿¾all age groups, per 100,000 populatio Figure 2 Acute viral hepatitis-associated mortality rates for child n, by year, Uzbekistan, 1985â€“1995 ren in various age groups, and reported acute viral hepatitis incidence in 
Acute viral hepatitis-associated mortality rates for children in various age groups, and reported acute viral 
hepatitis incidence in all age groups, per 100,000 population, by year, Uzbekistan, 1985â€“1995. Left ordinate (yï¿¾axis) and bar diagram: age- and gender-specific mortality: "black bars" â€“ mortality among boys; "white bars" â€“ mortality among 
girls, per 100,000 population of corresponding age and sex. Right ordinate (y-axis) and line diagram: reported acute viral hepaï¿¾titis incidence in the general population, per 100,000.
0
20
40
60
80
100
120
140
160
180
200
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995
Year
0
200
400
600
800
1000
1200
1400
1600
Age and gender specific mortality rates
Incidence per 100,000 population
Â•	

	
0
20
40
60
80
100
120
140
160
180
200
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995
Year
0
200
400
600
800
1000
1200
1400
1600
Age and gender specific mortality rates
Incidence per 100,000 population
	

	
0
20
40
60
80
100
120
140
160
180
200
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995
Year
0
200
400
600
800
1000
1200
1400
1600
Age and gender specific mortality rates
Incidence per 100,000 population
Â•	

	
0
20
40
60
80
100
120
140
160
180
200
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995
Year
0
200
400
600
800
1000
1200
1400
1600
Incidence per 100,000 population
Age and gender specific mortality rates
Â•	

	

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 6 of 9
(page number not for citation purposes)
tality were observed among children aged â‰¥2 to <3 years
and among those 3 to 14 years during this same period,
reflecting at least in part the fact that older children had a
much smaller risk of AVH-associated mortality at the
height of the epidemic than did children aged <2 years.
From 1985 to 1995, significant gender differences in
AVH-associated mortality among children were observed.
Of 22,405 AVH-associated deaths, 11,793 deaths were
among males, of whom 10,024 (85%) were aged 0â€“14
years; 10,612 deaths were among females, of whom 7121
(67.1%) were aged 0â€“14 years (RR [of death among males
vs. females] = 1.27; 95% CI: 1.25â€“1.29, p < 0.001).
From 1985 to 1995, AVH-associated MRs ranged from 1.1
to 5.6 per 100,000 among males in different 5-year age
groups aged 15 to 49 years, and from 2.6 to 7.8 per
100,000 among males aged >50 [see Additional file 1].
Marked AVH-associated mortality was noted among
females aged 20â€“24 years and 25â€“29 years, with the highï¿¾est rates in these age groups in 1986 (21.4 and 19.6 per
100,000, respectively) and 1987 (19.0 and 18.5 per
100,000, respectively).
During 1985â€“1987, AVH-associated MRs were 12.3â€“17.8
per 100,000 for the general population. In 1985â€“1989,
AVH-associated MRs were consistently higher among
females than among males in several age groups: 15â€“19
years; 20â€“24 years; 25â€“29 years; and 30â€“34-years [see
Additional file 1]. In this same time period, among perï¿¾sons aged >40 years, females consistently had lower AVHï¿¾associated MRs than did males (1.8â€“3.5 vs. 2.7â€“6.9 per
100,000; p < 0.01). In 1986, among persons aged 20â€“24
years, AVH-associated mortality among females was more
than 7 times that of males (21.4 vs. 2.9 per 100,000; p <
0.001) [see Additional file 1]. Among persons aged 15â€“19
years in 1993, there was an abrupt increase in AVH-assoï¿¾ciated mortality among females (11.7 per 100,000
females vs. 3.5 per 100,000 males) despite a decrease in
the AVH incidence rate in the general population [see
Additional file 1]. This dramatic rise in mortality was not
observed in any other age group.
The geographic distribution of AVH-associated mortality
varied: highest viloyat MRs were reported in 1987 in the
Eastern viloyats (Fergana, Namangan, and Andijan: range
20.1 to 31.0 per 100,000) and in the South (Kashkadarya,
and Surkhandarya: range 23.0 to 25.0 per 100,000). From
1985 through 1995, AVH-associated MRs were higher in
rural rather than in urban populations, with decreasing
trends in both populations: 21.0/8.0 (RR= 2.6; 95% CI:
1.16â€“5.93, p < 0.05) per 100,000 rural/urban population
in 1988; 18.0/6.5 (RR = 2.6; 95% CI: 1.07â€“6.16, p < 0.05)
in 1989; 12.4/4.8 (RR = 2.4; 95% CI: 0.85â€“6.81, p = n.s.)
in 1990; 9.3/7.0 (RR = 1.3; 95% CI: 0.48â€“3.45, p = n.s.) in
1991; 8.4/3.8 (RR = 2; 95% CI: 0.6â€“6.64, p = n.s.) in 1992
and 3.4/3.2 (RR = 1.1; 95% CI: 0.2â€“4.95, p = n.s.) in 1993.
HEV Serology
Of 396 adults and children with AVH for whom serum
samples were available from the 1987 epidemic in southï¿¾ern and eastern Uzbekistan (Kashkadarya and Fergana
viloyats), 280 (70.7%) were IgG anti-HEV positive; of
these, 221 (78.9%) were also IgM anti-HEV positive.
Among children with AVH, IgG anti-HEV was detected in
18/58 (31.0%) of those aged <3 years, 22/32 (68.7%) of
those aged 3â€“6 years, 21/37 (56.7%) of those aged 7â€“10
years, and 20/35 (57.1%) of those aged 11â€“14 years (p =
n.s.). The highest anti-HEV IgG prevalence was found
among those aged 20â€“29 years (104/122; 85.2%); and
30â€“39 years (52/63; 82.5%). Evidence of acute HAV infecï¿¾tion (i.e., IgM anti-HAV) was found in 78 of the 396
(19.7%) and acute HBV infection (i.e., IgM anti-HBc) in
33 of the 396 (8.3%); acute HDV infection (i.e., anti-HDV
IgM and anti-HDV) in 3 (0.8%), and acute mixed infecï¿¾tion with HAV and HBV in 2 (0.5%); none of these was
IgM anti-HEV positive.
Of 99 pregnant women with AVH for whom serum samï¿¾ples were available from 1992 from Tashkent viloyat, 12
(12%) tested positive for IgM and IgG anti-HEV, with one
AVH-associated death (8%; 95% CI 4â€“40); 55 (55%) had
evidence of acute HBV infection, with one AVH-associated
death (2%; 95% CI 0.1â€“10); 16 had acute HDV superinï¿¾fection, and two of these had AVH-associated deaths
(12.5%; 95% CI 2â€“40).
Discussion
This study documented sustained high AVH incidence
over a 35-year period in Uzbekistan and two large AVH
epidemics, the latter of which was associated with docuï¿¾mented acute HEV infection in serum specimens gathered
from AVH cases hospitalized during the epidemic. During
both of these epidemics, a dramatic increase in AVH-assoï¿¾ciated mortality was observed among females 15â€“39 years
of age, and in the first of these epidemics, among children
<3 years of age. Among children, reported AVH-associated
mortality was significantly higher among boys than
among girls. Reported AVH incidence and AVH-associated
mortality during these epidemics were 2â€“3 times higher in
rural areas than in urban areas. As these epidemics waned,
the mortality rate for women of childbearing age
decreased dramatically. Similar hepatitis E epidemics
have also been documented in adjacent, less-densely popï¿¾ulated republics, â€“ in 1983â€“1984 in Turkmenistan immeï¿¾diately to the West [5], and in 1986â€“1987 in Tajikistan
and Kyrgyzstan immediately to the East [20].
In 1993, the rise in AVH-associated mortality in
Uzbekistan among women was relatively limited to those

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 7 of 9
(page number not for citation purposes)
aged 15-19 years; from the serologic data that we have preï¿¾sented and from the fact that the mortality was confined
to women of childbearing age, we posit that these data
reflected a hepatitis E outbreak relatively limited to perï¿¾sons under 20 years of age. In this case, the distribution of
ages affected may have reflected a cohort effect of HEV
immunity among older women of childbearing age who
were exposed in the 1985â€“1987 epidemics. In the more
recent years of this analysis, there was a marked decrease
in mortality among women aged 20â€“29 years associated
with the overall decrease in AVH incidence and mortality.
During 1991-1995, when AVH was not epidemic across
the whole population, the AVH-associated MR among
women aged 20-24 and 25-29 years ranged from 2.6 to
7.3 per 100,000 women. Based on these data, it appears
that HEV infection was a large contributor to the AVHï¿¾associated deaths during this period, most likely among
young pregnant women. In the absence of laboratory conï¿¾firmation, AVH-associated mortality among reproductive
age women may be of use as an indicator of HEV infecï¿¾tion.
Although the patterns of mortality observed among
women of childbearing age were consistent with observaï¿¾tions from previous descriptions of hepatitis E epidemics
[5,7,9-11], we have not identified previous populationï¿¾based reports of increased mortality among young chilï¿¾dren in association with HEV infection. However, from
these and other endemic areas, it has been reported that
younger children are more likely to have more severe disï¿¾ease than do persons in other age groups if infected with
HEV [21-27]. Although infant MRs before the epidemic
period that began in 1985 had been similar to those
found elsewhere on average in the former Soviet Union,
AVH-associated mortality in children under the age of 2
years in Uzbekistan was five times that observed on averï¿¾age across the former Soviet Union during this epidemic
period [13].
In reviewing the morbidity and mortality data presented
here, other causes of AVH were considered. The dramatic
increase in AVH-associated mortality in the youngest age
groups during the HEV epidemic period could not be
ascribed solely to either of the other two most common
causes of acute liver failure in the pediatric population in
this region, namely HAV infection or HBV infection. HAV
infection in young children in a highly endemic area is
almost always asymptomatic and rarely results in death
[8,13,28-30]. As for acute HBV infection, over the period
1985â€“1995, there was little fluctuation in documented
disease incidence in the youngest age groups in
Uzbekistan [6]. However, it is possible that the increase in
AVH-associated mortality observed in the youngest age
groups at least in part reflected HEV infection accompaï¿¾nied by another wide-spread cause of acute liver failure,
e.g., HAV or HBV co-infection, drug-induced liver failure,
or an environmental toxin. Indeed, it has been observed
that children with HAV and HEV co-infection have a
higher incidence of acute liver failure than do children
who do not have co-infection [31]. Both hepatotoxic
mycotoxin contamination of grain-based foodstuffs [32]
and hepatoxic pyrrolizidine-alkaloid ingestion as the
result of Heliotropium lasocarpium contamination in wheat
production [33-35] are well-described phenomena in the
region; and at least one case of hepatitis associated with
IgM anti-HEV antibodies has been described in a child,
developing after starting dapsone and resolving after disï¿¾continuing the medication, suggesting drug-induced
potentiation of hepatitis E [36]. However, no known AVH
etiology other than HEV was widely observed or suspected
among children in this region during 1985 through 1987.
Although the high mortality rate observed in this outï¿¾break among children under the age of 3 years, especially
those under the age of 2 years, suggests that this group
may be at greater risk for developing more severe forms of
AVH in a epidemic of hepatitis E, mortality case-specific
serology data were not available to determine whether any
other cause of acute liver failure may have contributed to
the increase in mortality.
In 1985 to 1987, when AVH mortality was greatest, there
was a mortality increase among those aged between 1 and
3 years that was much greater than that among infants
(children less than 1 year of age). Understandably, those
aged between 1 and 3 years generally would have a greater
exposure than infants because of the increased likelihood
of using water sources rather than continuing breast-feedï¿¾ing and because of greater mobility and access of the child
to sources of HEV exposure. Infections from contamiï¿¾nated food and water begin after breastfed babies are
weaned [37].
Protective factors in breast milk and maternal antibodies
could also explain why infants fared better than children
aged between 1 and 3 years in an environment with HEV
exposure: IgG antibodies cross the placenta well during
the third trimester [38], and secretory IgA antibodies and
other host defense factors in breast milk, such as lactoferï¿¾rin, lysozyme, and macrophages and granulocytes, can be
protective or mitigate infection [37,39]. Milk-excreted
antibodies play a role in protecting infants from infection
by pathogens having a mucosal portal of entry, such as
rotavirus [40,41]. However, in the 1985â€“1987 outbreak
described here, only 8â€“10% of all healthy women had
anti-HEV IgG in serum (data not shown), so one would
expect that only 8â€“10% of infants would have had materï¿¾nal antibody protection from HEV infection. In evaluating
future outbreaks, if only a small fraction of infants has
antibodies to HEV and if increases in hepatitis E-associï¿¾ated mortality observed among children between 1 and 3

BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 8 of 9
(page number not for citation purposes)
years of age are greater than those observed among
infants, alternative hypotheses will need to be considered
to explain this latter phenomenon.
Conclusion
Because morbidity and mortality from AVH are the result
of social, economic and environmental factors, the effecï¿¾tiveness of population-based viral hepatitis control measï¿¾ures depends on targeted, etiology-focused efforts
including implementation of virus-specific surveillance.
In the case of hepatitis E, the goal of such efforts is to
improve hygiene and to assist in determining potential
target populations for a highly efficacious, recombinant
vaccine that has been developed and tested but is not yet
available [42,43]. In Uzbekistan, surveillance based excluï¿¾sively on clinical and epidemiologic data has been inadeï¿¾quate; the only test routinely available for viral hepatitis
has been identification of HBsAg, with no other test readï¿¾ily available to differentiate viral hepatitis types. Because
studies of AVH mortality in the former Soviet Union have
lacked accurate etiology-specific data [13], morbidity staï¿¾tistics for specific viral hepatitis diagnoses have been unreï¿¾liable. However, our findings suggest that when AVH
incidence is compared with AVH-associated mortality, it
may be logical to make some inferences regarding probaï¿¾ble hepatitis etiologies. Ecological studies such as this can
serve to generate hypotheses for more definitive studies.
In addition to the known increased mortality among
young women of child-bearing age in association with an
epidemic of hepatitis E, the increased mortality observed
here among children up to 3 years of age merits evaluaï¿¾tion and corroboration in future outbreaks.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MBS collected statistical data, made the preliminary data
analyses, and drafted the manuscript. MOF conceived and
designed the study, supervised data collection and coordiï¿¾nation, and conducted quality control/quality assessment
of laboratory testing of specimens for IgM and IgG antiï¿¾body to HEV (IgM and IgG anti-HEV). TLY and GGO
supervised gathering of specimens and conducted laboraï¿¾tory testing including assays for markers of acute HAV
infection (IgM anti-HAV), field laboratory testing of specï¿¾imens for IgM and IgG antibody to HEV (IgM and IgG
anti-HEV); markers of acute HBV infection, HBsAg and
IgM antibody to hepatitis B core antigen (IgM anti-HBc);
and markers of acute HDV infection (IgM anti-HDV and
total anti-HDV). MSB participated in design of the study
and performed statistical analysis. HSM participated in
development of discussion and supervised study efforts.
TLC developed the design of the article, and contributed
substantially to description of methods, data collection,
and discussion of results. All authors read and approved
the final manuscript.
Additional material
Acknowledgements
The authors wish to express their gratitude to Dr. Umid Sharapov for 
assisting with data management and critical review, editing, and formatting 
of numerous drafts of the manuscript.
References
1. Doroshenko NV, Schastnyi EI, Iagodovskii VV, Abdullaeva FA, Staï¿¾khanova VM: [Specific immunity in preschool children at high
risk of infection with hepatitis A virus]. Vopr Virusol 1990,
35:26-29.
2. Beutels P, Musabaev EI, Van Damme P, Yasin T: The disease burden
of hepatitis B in Uzbekistan. J Infect 2000, 40:234-241.
3. Ruzibakiev R, Kato H, Ueda R, Yuldasheva N, Hegay T, Avazova D,
Kurbanov F, Zalalieva M, Tuichiev L, Achundjanov B, Mizokami M:
Risk factors and seroprevalence of hepatitis B virus, hepatitis
C virus, and human immunodeficiency virus infection in
Uzbekistan. Intervirol 2001, 44:327-332.
4. Viazov SO, Paladi NE, Mkhitarian AL, Gorbarets IP, Iavorkovskaia EK:
[The spread of delta infection in the USSR]. Zh Mikrobiol Epiï¿¾demiol Immunobiol 1989, 10:96-101.
5. Favorov MO, Khukhlovich PA, Zairov GK, Listovskaia EK, Arakelov
SA: [Clinico-epidemiological characteristics and diagnosis of
viral non-A, non-B hepatitis with fecal and oral mechanisms
of transmission of the infection]. Vopr Virusol 1986, 31:65-69.
6. [Public Health Reports, Uzbekistan. Statistical data, 1992â€“
1995.]. Tashkent: Ministry of Health, Republic of Uzbekistan; 1996. 
7. Favorov MO, Kuzin SN, Iashina TL, Zairov GK, Gurov AV, Shavaï¿¾khabov ShSh, Buriev AIa, Zhantemirov BU, Shakhgil'dian IV, Ketiladze
ES: [Characteristics of viral hepatitis non-A, non-B with fecalï¿¾oral mechanism of transmission of infection in southern
Uzbekistan.]. Vopr Virusol 1989, 34:436-442.
8. Makarova GI: [The territorial and age-related characteristics
of the distribution of patients with non-A, non-B viral hepaï¿¾titis infected via the fecal-oral mechanism in foci of elevated
viral hepatitis morbidity in the Uzbek SSR]. Zh Mikrobiol Epiï¿¾demiol Immunobiol 1989, 5:35-38.
9. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI: Incidence
and severity of viral hepatitis in pregnancy. Am J Med 1981,
70:252-255.
10. Viswanathan R: Infectious hepatitis in Delhi (1955â€“1956): a
critical study in epidemiology. Indian J Med Res 1957,
45(Suppl):1-30.
11. Margolis HS, Alter MJ, Hadler SC: Viral hepatitis. In Viral Infection
of Humans: Epidemiology and Control 4th edition. Edited by: Evans AS,
Kaslow RA. New York: Plenum Medical Book Co; 1997:363-418. 
12. Skidmore S: Overview of hepatitis E virus. Curr Infect Dis Rep
2002, 4:118-123.
13. Shakhanina IL, Ivlieva OM, Narkevich MI: [Infectious disease morï¿¾tality in the USSR.]. Zh Mikrobiol Epidemiol Immunobiol 1990,
8:53-57.
Additional file 1
Acute viral hepatitis associated mortality rates for various age groups, 
by sex and year, Uzbekistan, 1985â€“1995 (per 100,000 population of 
corresponding age and sex). The data provided represent acute viral hepï¿¾atitis-associated mortality rates per 100,000 population of corresponding 
age and sex, for various age groups, by sex and year, based on death cerï¿¾tificate data in Uzbekistan, 1985â€“1995.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-9-35-S1.doc]

Publish with BioMed Central and every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours â€” you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2009, 9:35 http://www.biomedcentral.com/1471-2334/9/35
Page 9 of 9
(page number not for citation purposes)
14. Sharapov MB, Favorov MO, Iashina TL, Onishchenko GG, Asadov
DA, Chorba TL: [Morbidity and mortality in acute viral hepï¿¾atitides in a hyperendemic region. The role of viral hepatitis
E]. Zh Mikrobiol Epidemiol Immunobiol 2000, 3:35-39.
15. Kuzin SN, Alatortseva GI, Buriev AIa, Umirov SE, Khasanov AKh,
Gol'tsov VA, Amiantova II, Nesterenko LN, Titaev AV, Sukhanova LL,
Borisova OV, Volynskaia EA, Dotsenko VV, Taimanov T, Nikolaev VL,
Kuzina LE, Fedorova OE, Sorokin DN, Borzykh OA, Malyshev NA,
Shakhgil'dian IV, Balaian MS, Zverev VV: [Propagation of hepatitis
E virus in an endemic and nonendemic regions]. Vopr Virusol
2002, 47(2):18-21.
16. Glass RI: The SANEPID service in the USSR. Public Health Rep
1976, 91(2):154-158.
17. Usmanov I, Favorov M, Chorba T: Universal immunization: the
principal approach to control of diphtheria in the Republic of
Tajikistan, 1993â€“1997. J Infect Dis 2000, 18(Suppl 1):S86-S93.
18. Niyazmatov BI, Shefer A, Grabowsky M, Vitek CR: Diphtheria epiï¿¾demic in the Republic of Uzbekistan, 1993â€“1996. J Infect Dis
2000, 181(Suppl 1):S104-S109.
19. Favorov MO, Khudyakov YE, Mast EE, Yashina TL, Shapiro CN, Khudï¿¾yakova NS, Jue DL, Onischenko GG, Margolis HS, Fields HA: IgM
and IgG antibodies to hepatitis E virus (HEV) detected by an
enzyme immunoassay based on an HEV-specific artificial
recombinant mosaic protein. J Med Virol 1996, 50:50-58.
20. Iarasheva DM, Shakhgil'dian IV, Aripov KhIa, Psarev VM, Kurbanov
MD, Akhmedov UA, Dzhumaev RB, Madaliev IM: [The epidemioï¿¾logical diagnosis of "fecal-oral" hepatitis E in Tajikistan.]. Zh
Mikrobiol Epidemiol Immunobiol 1993, 2:63-66.
21. Aggarwal R, Naik SR: Hepatitis E in children. Indian Pediatr 1995,
32:271-275.
22. Arankalle VA, Jha J, Favorov MO, Chaudhari A, Fields HA, Banerjee
K: Contribution of HEV and HCV in causing fulminant nonï¿¾A, non-B hepatitis in western India. J Viral Hepatitis 1995,
2:189-193.
23. Tan D, Im SW, Yau JL, Ng MH: Acute sporadic hepatitis E virus
infection in southern China. J Hepatol 1995, 23:239-245.
24. Arora NK, Nanda SK, Gulati S, Ansari IH, Chawla MK, Gupta SD,
Panda SK: Acute viral hepatitis types E, A and B singly and in
combination in acute liver failure in children in north India.
J Med Virol 1996, 48:215-221.
25. Coursaget P, Buisson Y, N'Gawara MN, Van Cuyck-Gandre H, Roue
R: Role of hepatitis E virus in sporadic cases of acute and fulï¿¾minant hepatitis in an endemic area (Chad). Am J Trop Med
Hyg 1998, 58(3):330-334.
26. el-Zimaity DM, Hyams KC, Imam IZ, Watts DM, Bassily S, Naffea EK,
Sultan Y, Emara K, Burans J, Purdy MA, et al.: Acute sporadic hepï¿¾atitis E in an Egyptian pediatric population. Am J Trop Med Hyg
1993, 48(3):372-376.
27. Aggarwal R, Krawczynski K: Hepatitis E: an overview and recent
advances in clinical and laboratory research. J Gastroenterol
Hepatol 2000, 15:9-20.
28. Cuthbert JA: Hepatitis A: old and new. Clin Microbiol Rev 2001,
14:38-58.
29. Linder N, Karetnyi Y, Gidony Y, Ohel G, Levin E, Kuint J, Davidovich
N, Gidony I, Mendelson E, Barzilai A: Placental transfer of hepaï¿¾titis A antibodies in full term and preterm infants. Pediatr
Infect Dis J 1997, 16:245-247.
30. Lemon SM: Type A viral hepatitis: epidemiology, diagnosis,
and prevention. Clin Chem 1997, 43(8 Pt 2):1494-1499.
31. Acharya SK, Madan K, Dattagupta S, Panda SK: Viral hepatitis in
India. Natl Med J India 2006, 19:203-217.
32. L'vova LS, Orlova NIu, Bystriakova ZK, Omel'chenko MD, Remele
VV: [Propagation of toxigenic fungi and mycotoxins in variï¿¾ous grains.]. Prikl Biokhim Mikrobiol 1993, 29:70-79.
33. Askarov AA, Suleimonova GS, Askarov UA: [Dynamics of clinical,
biochemical and hepatic cytological changes of patients with
heliotrope toxicosis treated with dry plasma transfusions.].
Med Zh Uzb 1962, 9:8-12.
34. Chauvin P, Dillon JC, Moren A, Talbak S, Barakaev S: Heliotrope
poisoning in Tadjikistan. Lancet 1993, 341(8861):1663.
35. Chauvin P, Dillon JC, Moren A: [An outbreak of heliotrope food
poisoning, Tadjikistan, November 1992â€“March 1993]. SantÃ©
1994, 4(4):263-268.
36. Chogle A, Nagral A, Soni A, Agale S, Jamadar Z: Dapsone hypersenï¿¾sitivity syndrome with coexisting acute hepatitis E. Indian J
Gastroenterol 2000, 19:85-86.
37. Hanson LA, Soderstrom T: Human milk: Defense against infecï¿¾tion. Prog Clin Biol Res 1981, 61:147-159.
38. Englund J, Glezen WP, Piedra PA: Maternal immunization against
viral disease. Vaccine 1998, 16:1456-1463.
39. Chandra RK: Immunological aspects of human milk. Nutr Rev
1978, 36:265-272.
40. McLean B, Holmes IH: Transfer of antirotaviral antibodies from
mothers to their infants. J Clin Microbiol 1980, 12:320-325.
41. Perre P Van de: Transfer of antibody via mother's milk. Vaccine
2003, 21:3374-3376.
42. Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa
N, Myint KS, Fourneau M, Kuschner RA, Shrestha SK, David MP, Seriï¿¾watana J, Vaughn DW, Safary A, Endy TP, Innis BL: Safety and effiï¿¾cacy of a recombinant hepatitis E vaccine. N Engl J Med 2007,
356:895-903.
43. Purcell RH, Emerson SU: Hepatitis E: an emerging awareness of
an old disease. J Hepatol 2008, 48:494-503.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/9/35/prepub

